Cargando…

Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test

BACKGROUND: Acute kidney injury (AKI) is common in patients with multiple myeloma (MM). Whether serum free light chain (sFLC) measurements can distinguish between myeloma and other causes of AKI requires confirmation to guide early treatment. A rapid and portable sFLC test (Seralite®) is newly avail...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heaney, Jennifer L. J., Campbell, John P., Yadav, Punit, Griffin, Ann E., Shemar, Meena, Pinney, Jennifer H., Drayson, Mark T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520226/ https://www.ncbi.nlm.nih.gov/pubmed/28728609 http://dx.doi.org/10.1186/s12882-017-0661-z

Ejemplares similares

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
por: Yadav, Punit, et al.
Publicado: (2018)

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
por: Heaney, Jennifer L. J., et al.
Publicado: (2018)

Serum free light chain level at diagnosis in myeloma cast nephropathy—a multicentre study
por: Yadav, Punit, et al.
Publicado: (2020)

Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure
por: Hutchison, Colin A, et al.
Publicado: (2008)

Light chain myeloma and detection of free light chains in serum and urine of dogs and cats
por: Harris, Robert Adam, et al.
Publicado: (2021)

Multiple myeloma: Detection of free monoclonal light chains by modified immunofixation electrophoresis with antisera against free light chains
por: Wilhite, Dorian, et al.
Publicado: (2021)

Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production
por: Khanim, F L, et al.
Publicado: (2011)

Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma
por: Willrich, Maria Alice V., et al.
Publicado: (2022)

Serum Free Light Chain Only Myeloma with Cytoplasmic IgM
por: Ebana, Hideaki, et al.
Publicado: (2014)

Serum free light chains and multiple myeloma: Is it time to extend their application?
por: Markovic, Uros, et al.
Publicado: (2020)

The Use of Kappa Free Light Chains to Diagnose Multiple Sclerosis
por: Arneth, Borros, et al.
Publicado: (2022)

Investigating the utility of saliva immunoglobulins for the detection of myeloma and using myeloma proteins to clarify partition between oral and systemic immunity
por: Heaney, Jennifer L. J., et al.
Publicado: (2022)

Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients
por: García de Veas Silva, José Luis, et al.
Publicado: (2016)

Improving the diagnostic pathway in patients presenting with acute kidney injury secondary to de novo multiple myeloma: a short report
por: Rana, Ritika, et al.
Publicado: (2021)

Active multiple myeloma suppresses and typically eliminates coexisting MGUS
por: Campbell, John P, et al.
Publicado: (2017)

Early Normalization of Free Light Chains Predicts Better Outcomes in Patients with Multiple Myeloma
por: Benson, Rony, et al.
Publicado: (2020)

Light Chain Myeloma Precipitating Cryoglobulinemic Vasculitis
por: Saeed, Bilal, et al.
Publicado: (2023)

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements
por: Dejoie, Thomas, et al.
Publicado: (2018)

Association between urinary free light chains and progression to end stage renal disease in chronic kidney disease
por: Fenton, Anthony, et al.
Publicado: (2018)

INDEPENDENT SYNTHESIS OF LIGHT AND HEAVY CHAINS : Quantitation of Light-Chain Production by Mouse Myeloma Variants
por: Laskov, Reuven, et al.
Publicado: (1974)

Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)
por: Holzhey, Tanja, et al.
Publicado: (2021)

Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response to Therapy
por: Moustafa, Muhamad Alhaj, et al.
Publicado: (2015)

Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients
por: Pendón-Ruiz de Mier, M. Victoria, et al.
Publicado: (2020)

Role of serum‐free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma
por: Tacchetti, Paola, et al.
Publicado: (2022)

Light-Chain Multiple Myeloma: A Diagnostic Challenge
por: Silva, Cristina, et al.
Publicado: (2021)

Crystalline light chain cast nephropathy in multiple myeloma
por: Lin, Zi-Shan, et al.
Publicado: (2021)

Multiple myeloma with acute light chain cast nephropathy
por: Leung, Nelson, et al.
Publicado: (2023)

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
por: Lopez-Anglada, Lucia, et al.
Publicado: (2018)

Establishing the best combination of the kappa free light chain index and oligoclonal bands for an accurate diagnosis of multiple sclerosis
por: Monreal, Enric, et al.
Publicado: (2023)

Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management
por: Chicca, Ilaria J., et al.
Publicado: (2020)

Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy
por: Hutchison, Colin A, et al.
Publicado: (2012)

Combination of bortezomib-based chemotherapy and extracorporeal free light chain removal for treating cast nephropathy in multiple myeloma
por: Bachmann, Ulrike, et al.
Publicado: (2008)

Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma
por: Schieferdecker, Aneta, et al.
Publicado: (2020)

Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma
por: Claveau, Jean-Sébastien, et al.
Publicado: (2022)

Evaluation of Correlation between Serum Free Light-Chain Assay and Bone Marrow Study in Multiple Myeloma Patients
por: Zamani, Fatemeh, et al.
Publicado: (2021)

Impacts of the COVID-19 Pandemic on Assessment of M-Protein and Free Light Chain Levels in Patients with Multiple Myeloma
por: Roose, James, et al.
Publicado: (2022)

Can urine studies be replaced by serum free light chains measurements to assign responses in multiple myeloma patients?
por: Cárdenas, Maria Cruz, et al.
Publicado: (2022)

Fibrillary inclusions in light chain proximal tubulopathy associated with myeloma
por: Neild, G. H., et al.
Publicado: (2012)

Cerebellar ataxia and sensory ganglionopathy associated with light-chain myeloma
por: Zis, Panagiotis, et al.
Publicado: (2017)

Limited value of serum neurofilament light chain in diagnosing amyotrophic lateral sclerosis
por: Davies, Jennifer C, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s1b9av0cc8e2egsmdi7dc7hhln